Trial 2N-21-5


PhI-113/NCI 10327: A Phase 1 Trial of MLN0128 (sapanisertib) and Telaglenastat CB-839) HCl iin Advanced NSCLC Patients

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: No
USC Satellite Location: USC Koreatown
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Grace Facio, R.N., Marissa Aldana, Coordinator, Kristy Sartor Massopust, Coordinator, Eduardo Mejia, D.M., Brigitte Torres, Coordinator, Sreebharathy Venkatesh, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.